ClinicalTrials.gg
CompletedNCT05225857Updated Feb 5, 2024

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

A Phase 1 interventional study of AGA2118 and Placebo in Osteoporosis, sponsored by Angitia Biopharmaceuticals. Completed at 2 sites in Australia. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by Angitia Biopharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Osteoporosis with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis · Australia.

Enrollment
22nd of 32
90 · median 188
Started
2022
with 1 other
Phase 1
3 of 33
none open now
Registered
31st of 33
by date
Lead sponsor
1 of 33
Angitia Biopharmaceuticals

Among the 33 studies in Osteoporosis with a site in Australia, this one is the 22nd largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 31st registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

1 of the 33 studies in Osteoporosis with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteoporosis with a site in Australia, or all of them as a file.
02

Study summary

The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations in men and postmenopausal women.

Read the detailed description

This is a Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women.

The study consists of the single ascending dose (SAD) part and the multiple ascending dose (MAD) part. In the SAD part, up to 56 healthy men and postmenopausal women will be sequentially enrolled to receive a single subcutaneous (SC) dose of AGA2118 or a single intravenous (IV) dose of AGA2118 or placebo. In the MAD part, up to 32 healthy men and postmenopausal women will be sequentially enrolled in various dose cohorts to receive multiple SC doses every 4 weeks of AGA2118 or placebo.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men ≥ 30 and ≤ 65 years of age or women ≥ 45 and ≤ 65 years of age for SAD and MAD;
  2. ≥ 18.5 and ≤ 32 kg/m\^2 (for SAD and MAD).
  3. Generally healthy (as assessed by the investigator).
  4. Nonsmokers, or light smokers, defined as ≤ 3 cigarettes/day (or equivalent) (for SAD and MAD).
  5. Able and willing to correctly and independently complete all study procedures and able to read, understand, and provide written after the nature of the study has been fully explained and must be willing to comply with all study requirements and procedures (for SAD and MAD).
  6. A male who is sterile or agrees to the following during the Treatment Period and for at least 6 months after the final dose of product

    • Refrain from donating fresh unwashed semen

Plus, either

  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent

OR

  • Must agree to use as detailed below

    • Agree to use a male condom plus a female partner to use a highly effective method of contraception with a woman of who is not currently pregnant
    • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person

Exclusion criteria

Exclusion Criteria:

  1. A bone fracture within 6 months (for SAD only).
  2. Previous exposure to AGA2118 (for MAD only).
  3. Any condition that would affect bone metabolism or has a history of low energy fractures as documented in medical history (for MAD only).
  4. Administration of the any medications that known to affect bone metabolism within 6 months of Day 1 unless otherwise specified (for SAD and MAD).
  5. (HIV) infection (for SAD and MAD).
  6. Active chronic (HBV) or (HCV) infection including hepatitis B surface antigen and hepatitis C antigen positive participants with or without abnormal liver enzymes (for SAD and MAD).
  7. Evidence of any of the following (for SAD and MAD):

    1. creatinine ≥ 1.5 × , or estimated (eGFR) \< 60 mL/min/1.73 m\^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula at screening
    2. current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range
    3. known intolerance to calcium supplements
    4. within the last 5 years, etc.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    AGA2118

    In SAD part, various single doses of AGA2118 will be administered to the participants via either SC injection or IV infusion. The starting dose was 0.3 mg/kg, with sequential escalation up to 15 mg/kg. In MAD part, various multiple doses of AGA2118 will be administered every four weeks (Q4W) to the participants via SC injection for 12 weeks. The starting dose was 1 mg/kg, with sequential escalation up to 12 mg/kg.

    Drug: AGA2118

  • Placebo comparator
    Placebo

    In SAD part, a single dose of placebo comparator will be used for each cohort of either SC or IV administration. In MAD part, multiple doses of placebo comparator will be used for each cohort of SC administration.

    Drug: Placebo

Interventions

  • Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.

  • DrugPlacebo

    Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV. Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAE) in Part 1 (SAD).

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP.

    Time frame: Up to 85 days

  2. Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 1 (SAD).

    Serum calcium tested at Day 2, 4, 6, 15, 29, 85.

    Time frame: Up to 85 days

  3. Number of participants with clinically significant changes in blood pressure in Part 1 (SAD).

    Systolic and diastolic blood pressure measured (mmHg) at all clinic visits (Day 1, 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 43, 57, 71, 85).

    Time frame: Up to 85 days

  4. Number of participants with clinically significant changes in heart rate in Part 1 (SAD).

    Heart rate measured by electrocardiogram (ECG) on Day 1, 2, 4, 6, 15, 29, 85.

    Time frame: Up to 85 days

  5. Number of participants with clinically significant changes in QTcF in Part 1 (SAD).

    QTcF (QT interval corrected for heart rate using Fridericia's formula) measured by electrocardiogram (ECG) on Day 1, 2, 4, 6, 15, 29, 43, 57, 71, 85.

    Time frame: Up to 85 days

  6. Number of participants with treatment-emergent adverse events (TEAE) in Part 2 (MAD).

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP.

    Time frame: Up to 169 days

  7. Number of participants with clinically significant changes in total calcium (albumin-adjusted) in Part 2 (MAD).

    Serum calcium tested at Day 2, 8, 15, 29, 36, 57, 64, 85, 169.

    Time frame: Up to 169 days

  8. Number of participants with clinically significant changes in blood pressure in Part 2 (MAD).

    Systolic and diastolic blood pressure measured (mmHg) at all clinic visits (Day 1, 2, 4, 6, 8, 15, 22, 29, 36, 43, 57, 58, 60, 62, 64, 71, 78, 85, 99, 113, 127, 141, 155, 169).

    Time frame: Up to 169 days

  9. Number of participants with clinically significant changes in heart rate in Part 2 (MAD).

    Heart rate measured by electrocardiogram (ECG) on Day 1, 2, 4, 15, 29, 36, 57, 64, 85, 169.

    Time frame: Up to day 169

  10. Number of participants with clinically significant changes in QTcF in Part 2 (MAD).

    QTcF (QT interval corrected for heart rate using Fridericia's formula) measured by electrocardiogram (ECG) on Day 1, 2, 4, 15, 29, 36, 57, 64, 85, 169.

    Time frame: Up to day 169

Secondary outcomes

  1. Maximum Concentration (Cmax) of AGA2118

    Maximum concentration of AGA2118 after dosing.

    Time frame: Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169

  2. Time to maximum concentration (Tmax) of AGA2118

    Time to maximum concentration of AGA2118 after dosing.

    Time frame: Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169

  3. Area under the concentration time curve (AUC)

    Definite integral of the curve describing the variation of AGA2118 in blood as a function of time.

    Time frame: Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169

  4. Terminal elimination half-life (t1/2)

    Time it takes for maximum concentration to half of maximum concentration of AGA2118.

    Time frame: Part 1 (SAD): up to day 85; Part 2 (MAD) up to day 169

07

Study locations

2 sites
  • Q-Pharm Pty Ltd
    Brisbane, Queensland 4006, Australia
  • Nucleus Network Pty Ltd.
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2024, 18 months.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Feb 7, 2022
StartActual
Jun 28, 2022
Primary completionActual
Jan 13, 2024
CompletionActual
Jan 13, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05225857
Lead sponsor
Angitia Biopharmaceuticals
Collaborators
Angitia Australia Pty Ltd
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Jun 28, 2022
Primary completion
Jan 13, 2024
Completion
Jan 13, 2024
Last update
Feb 5, 2024

Study contacts

Angitia Medical Director
study director · Angitia Incorporated Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AGA2118

Start the discussion